Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$127.20

-5.25 (-3.96%)

04:56
11/10/17
11/10
04:56
11/10/17
04:56

Puma Biotechnology price target raised to $122 from $103 at Barclays

Barclays analyst Gena Wang raised her price target for Puma Biotechnology to $122 citing encouraging Nerlynx launch metrics post the company's Q3 results. The analyst maintains an Overweight rating on the shares.

  • 14

    Nov

PBYI Puma Biotechnology
$127.20

-5.25 (-3.96%)

10/27/17
LEER
10/27/17
NO CHANGE
Target $140
LEER
Outperform
Puma Biotechnology price target raised to $140 from $125 at Leerink
Leerink analyst Michael Schmidt raised his price target for Puma Biotechnology to $140 after conducting a survey of 45 U.S. oncologists to gain additional insights into the market potential of Nerlynx in HER2+ breast cancer. About a third of those surveyed have already prescribed Nerlynx commercially, with most doctors indicating that the drug would be best suited for treating nodepositive, hormone receptor positive, HER2+ breast cancer patients that have received adjuvant, Herceptin therapy, Schmidt tells investors in a research note. The analyst believes Nerlynx continues to look well-positioned competitively. He keeps an Outperform rating on Puma shares.
10/05/17
SBSH
10/05/17
NO CHANGE
Target $156
SBSH
Buy
Citi doubles down on Puma buyout thesis, boosts price target to $156
Citi analyst Yigal Nochomovitz raised his price target for Puma Biotechnology to $156 from $114 saying the stock has more upside even after rallying 280% year-to-date. Puma closed yesterday up 5% to $123.00 after JPMorgan analyst Cory Kasimov boosted his price target to $131. Nochomovitz notes that as far back as Q1 of 2016, he identified Puma as a "logical acquisition target." With the shares above his prior price target, the analyst feels the "time is right to fully flex" his acquisition thesis. At $156 per share, Puma would be a $6B company, which "only" implies a four-times multiple on a peak Nerlynx sales estimate of $1.4B, Nochomovitz tells investors in a research note partially titled "The Big Cat Roars into Her Final Sprint." Even if Puma raises debt, which would make sense now that the company has a de-risked commercial asset, it would not detract from the takeover thesis, the analyst adds. Nochomovitz keeps a Buy rating.
10/04/17
JPMS
10/04/17
NO CHANGE
Target $131
JPMS
Overweight
JPMorgan ups Puma target to $131 after surveying 25 oncologists
JPMorgan analyst Cory Kasimov raised his price target for Puma Biotechnology shares to $131 from $105 after surveying 25 oncologists to better gauge the launch of Nerlynx for breast cancer. In a research note titled "Survey Says . . . Nerlynx Looks Poised to Pounce," Kasimov says the survey suggests a "possible materially stronger than anticipated launch." He believes shares still have upside potential as Nerlynx's sales trajectory "appears underappreciated." The analyst reiterates an Overweight rating on Puma shares. The biopharmaceutical company closed yesterday down $2.85 to $117.00.
09/27/17
FBCO
09/27/17
NO CHANGE
Target $136
FBCO
Outperform
Puma NERLYNX survey shows stronger trends in early days, says Credit Suisse
Credit Suisse analyst Alethia Young says a Puma Biotechnology NERLYNX doctor survey showed that trends look strong in early days of launch. The analyst ran a survey of 75 breast cancer doctors in the US, and says about 50% of doctors have written scripts already, over half of the surveyed doctors would prescribe in HR-, which may broaden the market opportunity and diarrhea remains the most common concern around prescribing. The analyst reiterates an Outperform rating and $136 price target on the shares.

TODAY'S FREE FLY STORIES

UIS

Unisys

$7.55

0.25 (3.42%)

07:53
11/22/17
11/22
07:53
11/22/17
07:53
Hot Stocks
Unisys selected by New Zealand Ministry of Education for resourcing system »

Unisys has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

QADA

QAD Inc.

$39.95

1.75 (4.58%)

07:51
11/22/17
11/22
07:51
11/22/17
07:51
Recommendations
QAD Inc. analyst commentary  »

QAD Inc. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

07:48
11/22/17
11/22
07:48
11/22/17
07:48
Downgrade
Cytokinetics rating change  »

Cytokinetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

07:46
11/22/17
11/22
07:46
11/22/17
07:46
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:45
11/22/17
11/22
07:45
11/22/17
07:45
General news
U.S. MBA mortgage market index rose 0.1% »

U.S. MBA mortgage market…

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

07:43
11/22/17
11/22
07:43
11/22/17
07:43
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$139.23

2.31 (1.69%)

07:43
11/22/17
11/22
07:43
11/22/17
07:43
Technical Analysis
Technical View: Deere at new 52-week high after results beat expectations »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

CRM

Salesforce

$108.80

1.43 (1.33%)

07:42
11/22/17
11/22
07:42
11/22/17
07:42
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:40
11/22/17
11/22
07:40
11/22/17
07:40
General news
Treasury Market Outlook: longer dated bond yields are modestly higher »

Treasury Market Outlook:…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

07:39
11/22/17
11/22
07:39
11/22/17
07:39
Technical Analysis
Technical View: Axalta Coating up on Nippon Paint takeover talks »

The company earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.44 (1.34%)

07:39
11/22/17
11/22
07:39
11/22/17
07:39
Recommendations
Salesforce analyst commentary  »

Canaccord has 'no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

OSUR

OraSure

$16.55

2.59 (18.55%)

07:36
11/22/17
11/22
07:36
11/22/17
07:36
Recommendations
OraSure analyst commentary  »

OraSure contract win…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.73

0.29 (1.76%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Technical Analysis
Technical View: GameStop trades higher after earnings and outlook »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$14.67

0.15 (1.03%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Recommendations
Nuance analyst commentary  »

In-line guidance likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AAPL

Apple

$173.14

3.16 (1.86%)

, BAC

Bank of America

$26.73

-0.01 (-0.04%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AAPL

Apple

$173.14

3.16 (1.86%)

BAC

Bank of America

$26.73

-0.01 (-0.04%)

MU

Micron

$49.40

1.76 (3.69%)

T

AT&T

$34.33

-0.31 (-0.89%)

ORCL

Oracle

$48.63

-0.39 (-0.80%)

AKS

AK Steel

$4.85

0.22 (4.75%)

PG

Procter & Gamble

$88.72

0.45 (0.51%)

TRIP

TripAdvisor

$32.81

2.33 (7.64%)

PEP

PepsiCo

$116.05

1.14 (0.99%)

PAGP

Plains GP Holdings

$20.48

-0.41 (-1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 29

    Nov

  • 19

    Dec

EKSO

Ekso Bionics

$4.13

1.21 (41.44%)

07:33
11/22/17
11/22
07:33
11/22/17
07:33
Technical Analysis
Technical View: Ekso Bionics trades sharply higher, edging 52-week high »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$30.20

0.5 (1.68%)

07:32
11/22/17
11/22
07:32
11/22/17
07:32
Initiation
Nutanix initiated  »

Nutanix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 07

    Dec

  • 12

    Dec

HPE

HP Enterprise

$14.12

0.03 (0.21%)

07:32
11/22/17
11/22
07:32
11/22/17
07:32
Recommendations
HP Enterprise analyst commentary  »

HP Enterprise CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 11

    Dec

GE

General Electric

$17.83

-0.15 (-0.83%)

, DKS

Dick's Sporting

$28.58

-0.52 (-1.79%)

07:30
11/22/17
11/22
07:30
11/22/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$17.83

-0.15 (-0.83%)

DKS

Dick's Sporting

$28.58

-0.52 (-1.79%)

ROST

Ross Stores

$72.67

-0.07 (-0.10%)

ILG

ILG

$28.11

-0.5 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 12

    Dec

DLTR

Dollar Tree

$99.46

2.35 (2.42%)

07:29
11/22/17
11/22
07:29
11/22/17
07:29
Recommendations
Dollar Tree analyst commentary  »

Dollar Tree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:28
11/22/17
11/22
07:28
11/22/17
07:28
General news
Futures above fair value ahead of holiday »

Stock futures are…

SHOO

Steven Madden

$39.80

-0.6 (-1.49%)

07:28
11/22/17
11/22
07:28
11/22/17
07:28
Conference/Events
Steven Madden management to meet with Buckingham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

BURL

Burlington Stores

$104.94

-1.61 (-1.51%)

07:25
11/22/17
11/22
07:25
11/22/17
07:25
Recommendations
Burlington Stores analyst commentary  »

Burlington Stores price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLH

Red Lion Hotels

$8.55

0.1 (1.18%)

07:24
11/22/17
11/22
07:24
11/22/17
07:24
Conference/Events
Red Lion Hotels management to meet with Craig Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 30

    Nov

  • 06

    Dec

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

07:24
11/22/17
11/22
07:24
11/22/17
07:24
Recommendations
TiVo, Comcast, Comcast analyst commentary  »

TiVo ITC win raises odds…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.